APA (7th ed.) Citation

Emberley, E., Pan, A., Chen, J., Dang, R., Gross, M., Huang, T., . . . Parlati, F. (2021). The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma. Public Library of Science (PLoS).

Chicago Style (17th ed.) Citation

Emberley, Ethan, et al. The Glutaminase Inhibitor Telaglenastat Enhances the Antitumor Activity of Signal Transduction Inhibitors Everolimus and Cabozantinib in Models of Renal Cell Carcinoma. Public Library of Science (PLoS), 2021.

MLA (8th ed.) Citation

Emberley, Ethan, et al. The Glutaminase Inhibitor Telaglenastat Enhances the Antitumor Activity of Signal Transduction Inhibitors Everolimus and Cabozantinib in Models of Renal Cell Carcinoma. Public Library of Science (PLoS), 2021.